B cell modulation strategies in autoimmunity: The SLE example

M. Manuela Rosado, Andrea Picchianti Diamanti, Federica Capolunghi, Rita Carsetti

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The paradigm that T cells are the prime effectors of autoimmune diseases has been recently challenged by growing evidence that B-lymphocytes play a role in the development, re-activation and persistence of autoimmune disorders. B-cells of different subsets may play different roles in autoimmune pathologies due to their ability to secrete antibodies, produce cytokines, present antigen and form ectopic germinal centers. Thus, a given therapeutic approach or drug may have distinct outcomes depending on which specific B cell subset is targeted. Immunosuppressive therapies such as azathioprine (AZA), cyclophosphamide (CyC) or methotrexate (MTX) are conventionally used in autoimmune diseases with the aim of reducing disease activity and improving the patient's general health conditions. These treatments do not target a specific cellular type or subset and have substantial side effects, such as impairment of liver function and fertility. Moreover, autoimmune patients may be refractory to immunosuppressive therapy. In these cases finding an effective treatment becomes a challenge. The fast evolution in antibody technology is leading to the production of a wide array of humanized monoclonal antibodies, targeting specific cell types or pathways, initiating a new era in the treatment of autoimmune disorders. In addition, the recent discovery that toll like receptors (TLRs) activation can fire up autoimmunity in humans and maintain disease gives the grounds for the development of new drugs targeting the TLR/MyD88 pathway. In contrast to conventional immune-suppression, the availability of drugs interfering with B-cell specific pathogenetic pathways gives the possibility to choose therapies tailored to each disease and, possibly, to each patient.

Original languageEnglish
Pages (from-to)3155-3165
Number of pages11
JournalCurrent Pharmaceutical Design
Volume17
Issue number29
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Autoimmunity
B-Lymphocytes
B-Lymphocyte Subsets
Toll-Like Receptors
Immunosuppressive Agents
Therapeutics
Autoimmune Diseases
Antibodies, Monoclonal, Humanized
Germinal Center
Antibodies
Azathioprine
Drug Delivery Systems
Methotrexate
Pharmaceutical Preparations
Cyclophosphamide
Fertility
Pathology
Cytokines
Technology
T-Lymphocytes

Keywords

  • Autoantibodies
  • B cells
  • Biologic drugs
  • SLE

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

B cell modulation strategies in autoimmunity : The SLE example. / Rosado, M. Manuela; Diamanti, Andrea Picchianti; Capolunghi, Federica; Carsetti, Rita.

In: Current Pharmaceutical Design, Vol. 17, No. 29, 10.2011, p. 3155-3165.

Research output: Contribution to journalArticle

Rosado, M. Manuela ; Diamanti, Andrea Picchianti ; Capolunghi, Federica ; Carsetti, Rita. / B cell modulation strategies in autoimmunity : The SLE example. In: Current Pharmaceutical Design. 2011 ; Vol. 17, No. 29. pp. 3155-3165.
@article{81d40b0746a24492abc356ab23c32355,
title = "B cell modulation strategies in autoimmunity: The SLE example",
abstract = "The paradigm that T cells are the prime effectors of autoimmune diseases has been recently challenged by growing evidence that B-lymphocytes play a role in the development, re-activation and persistence of autoimmune disorders. B-cells of different subsets may play different roles in autoimmune pathologies due to their ability to secrete antibodies, produce cytokines, present antigen and form ectopic germinal centers. Thus, a given therapeutic approach or drug may have distinct outcomes depending on which specific B cell subset is targeted. Immunosuppressive therapies such as azathioprine (AZA), cyclophosphamide (CyC) or methotrexate (MTX) are conventionally used in autoimmune diseases with the aim of reducing disease activity and improving the patient's general health conditions. These treatments do not target a specific cellular type or subset and have substantial side effects, such as impairment of liver function and fertility. Moreover, autoimmune patients may be refractory to immunosuppressive therapy. In these cases finding an effective treatment becomes a challenge. The fast evolution in antibody technology is leading to the production of a wide array of humanized monoclonal antibodies, targeting specific cell types or pathways, initiating a new era in the treatment of autoimmune disorders. In addition, the recent discovery that toll like receptors (TLRs) activation can fire up autoimmunity in humans and maintain disease gives the grounds for the development of new drugs targeting the TLR/MyD88 pathway. In contrast to conventional immune-suppression, the availability of drugs interfering with B-cell specific pathogenetic pathways gives the possibility to choose therapies tailored to each disease and, possibly, to each patient.",
keywords = "Autoantibodies, B cells, Biologic drugs, SLE",
author = "Rosado, {M. Manuela} and Diamanti, {Andrea Picchianti} and Federica Capolunghi and Rita Carsetti",
year = "2011",
month = "10",
doi = "10.2174/138161211798157612",
language = "English",
volume = "17",
pages = "3155--3165",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "29",

}

TY - JOUR

T1 - B cell modulation strategies in autoimmunity

T2 - The SLE example

AU - Rosado, M. Manuela

AU - Diamanti, Andrea Picchianti

AU - Capolunghi, Federica

AU - Carsetti, Rita

PY - 2011/10

Y1 - 2011/10

N2 - The paradigm that T cells are the prime effectors of autoimmune diseases has been recently challenged by growing evidence that B-lymphocytes play a role in the development, re-activation and persistence of autoimmune disorders. B-cells of different subsets may play different roles in autoimmune pathologies due to their ability to secrete antibodies, produce cytokines, present antigen and form ectopic germinal centers. Thus, a given therapeutic approach or drug may have distinct outcomes depending on which specific B cell subset is targeted. Immunosuppressive therapies such as azathioprine (AZA), cyclophosphamide (CyC) or methotrexate (MTX) are conventionally used in autoimmune diseases with the aim of reducing disease activity and improving the patient's general health conditions. These treatments do not target a specific cellular type or subset and have substantial side effects, such as impairment of liver function and fertility. Moreover, autoimmune patients may be refractory to immunosuppressive therapy. In these cases finding an effective treatment becomes a challenge. The fast evolution in antibody technology is leading to the production of a wide array of humanized monoclonal antibodies, targeting specific cell types or pathways, initiating a new era in the treatment of autoimmune disorders. In addition, the recent discovery that toll like receptors (TLRs) activation can fire up autoimmunity in humans and maintain disease gives the grounds for the development of new drugs targeting the TLR/MyD88 pathway. In contrast to conventional immune-suppression, the availability of drugs interfering with B-cell specific pathogenetic pathways gives the possibility to choose therapies tailored to each disease and, possibly, to each patient.

AB - The paradigm that T cells are the prime effectors of autoimmune diseases has been recently challenged by growing evidence that B-lymphocytes play a role in the development, re-activation and persistence of autoimmune disorders. B-cells of different subsets may play different roles in autoimmune pathologies due to their ability to secrete antibodies, produce cytokines, present antigen and form ectopic germinal centers. Thus, a given therapeutic approach or drug may have distinct outcomes depending on which specific B cell subset is targeted. Immunosuppressive therapies such as azathioprine (AZA), cyclophosphamide (CyC) or methotrexate (MTX) are conventionally used in autoimmune diseases with the aim of reducing disease activity and improving the patient's general health conditions. These treatments do not target a specific cellular type or subset and have substantial side effects, such as impairment of liver function and fertility. Moreover, autoimmune patients may be refractory to immunosuppressive therapy. In these cases finding an effective treatment becomes a challenge. The fast evolution in antibody technology is leading to the production of a wide array of humanized monoclonal antibodies, targeting specific cell types or pathways, initiating a new era in the treatment of autoimmune disorders. In addition, the recent discovery that toll like receptors (TLRs) activation can fire up autoimmunity in humans and maintain disease gives the grounds for the development of new drugs targeting the TLR/MyD88 pathway. In contrast to conventional immune-suppression, the availability of drugs interfering with B-cell specific pathogenetic pathways gives the possibility to choose therapies tailored to each disease and, possibly, to each patient.

KW - Autoantibodies

KW - B cells

KW - Biologic drugs

KW - SLE

UR - http://www.scopus.com/inward/record.url?scp=80055086845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055086845&partnerID=8YFLogxK

U2 - 10.2174/138161211798157612

DO - 10.2174/138161211798157612

M3 - Article

C2 - 21864265

AN - SCOPUS:80055086845

VL - 17

SP - 3155

EP - 3165

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 29

ER -